4//SEC Filing
Karas Eric 4
Accession 0001415889-25-019321
CIK 0001671858other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 4:21 PM ET
Size
9.1 KB
Accession
0001415889-25-019321
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-07-01$16.99/sh−15,000$254,861→ 10,315 total - Exercise/Conversion
Common Stock
2025-07-01$1.50/sh+15,000$22,500→ 25,315 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-07-01−15,000→ 544,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F3]The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]Immediately exercisable.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001951287
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 4:21 PM ET
- Size
- 9.1 KB